Marksans Pharma — 360° view

Marksans Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹940 crore and net profit of ₹144 crore for the September 2026 quarter.

Marksans Pharma (NSE: MARKSANS) closed at ₹291.15 on 20 Nov 2026, up 50.8% over the past year. Its market capitalisation is ₹13,196 crore and it trades at 23.6 times earnings.

Share price
₹291.15 (20 Nov 2026)
Market cap
₹13,196 Cr (20 Nov 2026)
P/E
23.58 (20 Nov 2026)
Revenue
₹940 Cr (September 2026 quarter)
Net profit
₹144 Cr (September 2026 quarter)
ROCE
18.8% (FY26)
ROE
15.2% (FY26)
Book value
₹73.5 (FY26)
Dividend yield
0.31% (last 12 months to 20 Nov 2026)
52-week high / low
₹350.95 / ₹155.00 (20 Nov 2026)
1-year return
50.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: MARKSANS

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.